Moneycontrol
HomeNewsBusinessUflex says COVID-19 may propel development of sterile, anti-microbial packaging solutions
Trending Topics

Uflex says COVID-19 may propel development of sterile, anti-microbial packaging solutions

Uflex revenues could grow 12-15% in FY21, as new projects are commissioned during the year, Rajesh Bhatia, Group President (Finance & Accounts) & CFO UFlex told Moneycontrol

June 22, 2020 / 12:01 IST
Story continues below Advertisement

The coronavirus pandemic has opened up opportunities for innovation. Uflex, an FMCG and pharma package manufacturing firm expects COVID-19 to propel the development of sterile and anti-microbial packaging solutions.

In an interview with Moneycontrol, Rajesh Bhatia, Group President (Finance & Accounts) & CFO UFlex said: “Post COVID-19, the focus will be back on sustainable packaging including Recycling and Biodegradable packaging, which will continue to drive all conversations in the industry.”

Story continues below Advertisement

On the impact of COVID-19 on packaging sector and Uflex, Bhatia said, the business segment of ‘Flexible Packaging Films and Packaging’ in which UFlex operates is indispensable to FMCG (food packaging) and Pharmaceutical packaging and has remained unscathed. UFlex could continue its operations even during the lockdown, he said.

The company expects to achieve revenue growth of 12-15 percent in FY21 over FY20, as the new projects are commissioned during the year and it sees higher capacity utilisation levels at existing plants.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show